Entities / Company
Corcept Therapeutics.
American pharmaceutical company
- Reports this week
- 1
- Active events
- 3
- Connections
- 51
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
-
Corcept Therapeutics made required filings with the SEC regarding institutional holdings on June 16, 2026.Some support3 reports1 development inside
-
Celcuity Inc. and Corcept Therapeutics are noted for developing targeted therapies in the United States.Some support1 report1 development inside
-
Corcept Therapeutics is seeking final approval from the European Commission for a cancer therapy already approved in the US market.Some support1 report
Earlier this month
-
Several companies and ETFs, including Corcept Therapeutics, Nvidia, Viasat, and Brinker International, were noted for their market exposures on September 9, 2026.Some support2 reports
-
Investor activity regarding Corcept Therapeutics, including RBC boosting holdings and Amundi buying, was disclosed via SEC filings.Some support1 report1 development inside
-
Corcept Therapeutics disclosed insider trading activity via SEC filings.Some support1 report
One to three months ago
-
Corcept Therapeutics and Twist Bioscience are noted as holdings within the First Trust biotech fund.Some support1 report
-
Corcept Therapeutics submitted an NDA for relacorilant to the FDA and is evaluating it in combination with Roche's Avastin.Well supported4 reports
-
Geode Capital Management increased its stake in Corcept Therapeutics, while Morgan Stanley lifted its holdings and Renaissance Technologies trimmed its position.Some support2 reports
-
Morgan Stanley increased its stake in Corcept Therapeutics, and Norges Bank also bought a new stake in the company.Some support1 report
Gone quiet
No new reports in 90+ days-
Truist Financial raised the stock rating for Corcept Therapeutics, and a director sold company stock.Some support2 reports
-
Corcept Therapeutics faces patent litigation with Teva, a situation that Joon Lee has questioned.Some support1 report
-
Trump's pledge to unleash American oil and gas is linked to revenue growth forecasts for Corcept Therapeutics and the pharmaceuticals industry.Some support1 report
-
Corcept Therapeutics presented data from the CATALYST trial at the American Diabetes Association sessions.Speculative1 report
-
Corcept Therapeutics is developing drugs aimed at treating Amyotrophic Lateral Sclerosis (ALS).Speculative1 report
-
Corcept Therapeutics CEO Joseph K. Belanoff provided guidance on the company's future outlook.Some support2 reports1 development inside
-
Corcept Therapeutics is developing and marketing medications, while LGI Homes is constructing homes across the United States.Speculative1 report
-
The FDA approved Korlym for Cushing's syndrome on July 6, 2025.Speculative1 report1 development inside
-
A trial was conducted on July 4, 2025, testing the product Korlym for diabetes.Speculative1 report
-
Planet Fitness, VSE Corporation, and Corcept Therapeutics were noted as high-flying stocks under scrutiny on July 14, 2025.Some support1 report
-
Analyst maintained a Buy rating on Corcept Therapeutics on July 28, 2025.Some support1 report
-
Corcept Therapeutics, a California-based company, submitted new drug applications to the FDA and received analyst ratings.Some support2 reports
-
Corcept Therapeutics and Merck are noted as peers within the pharmaceuticals segment.Some support2 reports
-
Corcept Therapeutics shares added 38.7% on August 1, 2025, outpacing the S&P 500's 8.2% gain.Some support1 report
-
The new event lists company profiles for Freshworks, Corcept Therapeutics, and American Superconductor.Some support1 report
-
Corcept Therapeutics, Agilysys, and Varonis Systems were analyzed for investment risk on August 18, 2025.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Corcept Therapeutics this week
News at the entities that move Corcept Therapeutics most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Corcept Therapeutics
-
Morgan Stanley TransactionalFinancial firms including Morgan Stanley, Truist Financial, Jefferies Financial Group, and CIBC issued rating and price objective updates for Clearway Energy.Moves Corcept Therapeutics
-
Royal Bank of Canada TransactionalRoyal Bank of Canada raised its holdings in the Dimensional US Sustainability Core 1 ETF on June 19, 2026.Moves Corcept Therapeutics
-
European Commission StructuralA European Commission summit focused on strategic cooperation, minerals, and pivoting away from the United States toward the EU.Moves Corcept Therapeutics
-
Renaissance Technologies TransactionalRenaissance Technologies holds a significant stake in Lite Strategy, Inc., whose stock trades on the Nasdaq exchange.Moves Corcept Therapeutics
-
Norges Bank TransactionalNorges Bank bought a new position in Qualcomm shares, coinciding with buy ratings and price targets from TD Cowen, reported by MarketBeat.Moves Corcept Therapeutics
Connections
The 18 strongest of 51, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Joseph K. Belanoff Structural
Joseph K. Belanoff serves as the Chief Executive Officer of Corcept Therapeutics.
-
FDA Structural
Corcept Therapeutics submits new drug applications and NDAs to the FDA for regulatory review, culminating in a final decision.
-
Norges Bank Transactional
Norges Bank acquired a new stake/position in Corcept Therapeutics.
-
SEC Structural
Corcept Therapeutics must comply with ongoing regulatory requirements and filings set by the U.S. Securities and Exchange Commission.
-
Morgan Stanley Transactional
Morgan Stanley increased and subsequently reduced its investment holdings in Corcept Therapeutics.
-
Securities and Exchange Commission Structural
Corcept Therapeutics must operate within the regulatory framework established by the U.S. Securities and Exchange Commission.
-
Geode Capital Management Transactional
Geode Capital Management increased its financial stake in Corcept Therapeutics.
-
Royal Bank of Canada Transactional
RBC increased its investment holdings in Corcept Therapeutics stock.
Show all 18 connections
-
David Mahoney Transactional
David Mahoney, a director of Corcept Therapeutics, sold company stock.
-
European Commission Structural
Corcept Therapeutics is seeking final approval for a cancer therapy from the European Commission.
-
NeoGenomics Mentioned together
Both companies are noted as major holdings within biotech investment funds.
-
Halozyme Therapeutics Mentioned together
Both companies are included in the same First Trust investment fund.
-
Renaissance Technologies Transactional
Renaissance Technologies reduced its investment stake in Corcept Therapeutics.
-
Truist Financial Mentioned together
Truist Financial provided a stock rating on Corcept Therapeutics, establishing a co-mention pattern in financial coverage.
-
James Wilson Transactional
Director James Wilson sold company stock in Corcept Therapeutics.
-
California Shared context
Corcept Therapeutics is located and headquartered in California.
-
Twist Bioscience Mentioned together
Both companies are mentioned as holdings within various biotech investment funds.
-
Brinker International Mentioned together
No evidence was found regarding any direct or indirect relationship between Corcept Therapeutics and Brinker International.
History
Events by the month they beganSeptember 2026
3 events- Corcept Therapeutics is seeking final approval from the European Commission for a cancer therapy already approved in the US market.
- Several companies and ETFs, including Corcept Therapeutics, Nvidia, Viasat, and Brinker International, were noted for their market exposures on September 9, 2026.
- Corcept Therapeutics disclosed insider trading activity via SEC filings.
August 2026
2 eventsJuly 2026
2 eventsShow 1 earlier month
June 2026
19 events- Corcept Therapeutics made required filings with the SEC regarding institutional holdings on June 16, 2026.
- Celcuity Inc. and Corcept Therapeutics are noted for developing targeted therapies in the United States.
- Corcept Therapeutics submitted an NDA for relacorilant to the FDA and is evaluating it in combination with Roche's Avastin.
- Truist Financial raised the stock rating for Corcept Therapeutics, and a director sold company stock.
- Corcept Therapeutics faces patent litigation with Teva, a situation that Joon Lee has questioned.
- Trump's pledge to unleash American oil and gas is linked to revenue growth forecasts for Corcept Therapeutics and the pharmaceuticals industry.
- Corcept Therapeutics presented data from the CATALYST trial at the American Diabetes Association sessions.
- Corcept Therapeutics is developing drugs aimed at treating Amyotrophic Lateral Sclerosis (ALS).
- Corcept Therapeutics CEO Joseph K. Belanoff provided guidance on the company's future outlook.
- Corcept Therapeutics is developing and marketing medications, while LGI Homes is constructing homes across the United States.
- The FDA approved Korlym for Cushing's syndrome on July 6, 2025.
- A trial was conducted on July 4, 2025, testing the product Korlym for diabetes.
- Planet Fitness, VSE Corporation, and Corcept Therapeutics were noted as high-flying stocks under scrutiny on July 14, 2025.
- Analyst maintained a Buy rating on Corcept Therapeutics on July 28, 2025.
- Corcept Therapeutics, a California-based company, submitted new drug applications to the FDA and received analyst ratings.
- Corcept Therapeutics and Merck are noted as peers within the pharmaceuticals segment.
- Corcept Therapeutics shares added 38.7% on August 1, 2025, outpacing the S&P 500's 8.2% gain.
- The new event lists company profiles for Freshworks, Corcept Therapeutics, and American Superconductor.
- Corcept Therapeutics, Agilysys, and Varonis Systems were analyzed for investment risk on August 18, 2025.